Collegium Pharmaceutical, Inc. filings document regulatory disclosures for a commercial biopharmaceutical company with ADHD and pain-management medicines. Form 8-K reports cover operating results, earnings presentations, Regulation FD materials, guidance, material agreements, capital-structure matters and clinical or regulatory disclosures tied to the company's product portfolio.
Proxy materials describe shareholder voting matters, board composition, director nominations, board succession, executive compensation and governance practices. The filing record also captures product-related risk disclosures and formal public-company reporting for Collegium's Nasdaq-listed common stock.
Collegium Pharmaceutical, Inc. (COLL) reported third-quarter product revenue of $216.3 million, versus $209.4 million a year earlier, and net income of $21.8 million, versus $31.5 million. For the first nine months, product revenue was $609.7 million versus $575.1 million, while net income was $21.2 million versus $45.9 million. Third-quarter selling, general and administrative expense was $99.6 million, versus $67.1 million.
On May 12, 2026, the company completed the Azstarys acquisition for approximately $655.6 million in cash, subject to customary purchase-price adjustments. It funded the payment with approximately $355.6 million of cash on hand and a $300 million delayed-draw term loan; up to $135 million more may be payable if specified commercial and manufacturing milestones are achieved. Azstarys product revenue was $26.5 million in the third quarter.
Operating cash flow for the first nine months was $215.0 million versus $206.3 million; investing activities used $501.2 million, including $655.4 million for Azstarys, net of cash acquired. On October 15, 2026, Collegium paid $17 million under a settlement with Grünenthal; the agreement terminated the Nucynta license and related royalty obligations and assigned two patents to Collegium.
Collegium Pharmaceutical, Inc. reported third-quarter 2026 net revenue of $216.3 million, up 3% year over year. JORNAY PM revenue rose 24% to $51.9 million, while AZSTARYS generated $26.5 million in its first full quarter under Collegium ownership. The pain portfolio produced $138.0 million, down 18% year over year, including Nucynta Franchise revenue of $30.8 million, down 44%.
GAAP net income was $21.8 million versus $31.5 million a year earlier; adjusted net income was $75.2 million versus $87.3 million. Adjusted EBITDA was $121.6 million, down 9%. Collegium reaffirmed 2026 guidance of $825 to $855 million in product revenue, $190 to $200 million in JORNAY PM revenue, $65 to $75 million in AZSTARYS revenue, and $445 to $470 million in adjusted EBITDA. Cash from operations was $86.5 million; cash, cash equivalents and marketable securities totaled $144.8 million at quarter-end. The company expects to complete its $50 million accelerated share repurchase before year-end.
Vanguard Capital Management reported beneficial ownership of 1,621,026 shares of Collegium Pharmaceutical, Inc. common stock, or 4.97% of the class. It reported sole voting power over 245,798 shares and sole dispositive power over 1,621,026 shares, with no shared voting or dispositive power. Vanguard stated that investment companies and managed accounts have rights to receive or direct dividends and sale proceeds from the reported securities; no other person's interest exceeds 5%.
Collegium Pharmaceutical, Inc. (COLL) is the issuer of common stock for which Principal Global Investors reported beneficial ownership of 1,514,310 shares, or 4.7%, as of September 30, 2026. Principal Global Investors reported shared voting and shared dispositive power over 1,514,310 shares, with sole voting and sole dispositive power each reported as zero. The amendment identifies the position as ownership of 5% or less of the class.
Collegium Pharmaceutical, Inc. paid Grünenthal $17,000,000 under a settlement agreement resolving all disputes and claims between them.
The agreement terminated the Grünenthal License in its entirety and the Consent Agreement solely with respect to the Territory, effective October 15, 2026, following payment. Collegium’s royalty obligations under the license were fully and finally discharged, with no further royalties due. Grünenthal assigned certain patents related to the Nucynta Products and filed a motion to dismiss the Nucynta Litigation; the Consent Agreement otherwise remains in force.
Collegium Pharmaceutical, Inc. (COLL) is the issuer in an amended ownership report: Integrated Core Strategies (US) LLC reports beneficial ownership of 1,897,471 shares (5.8%). Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report 2,400,985 shares (7.4%).
All four report shared voting and shared dispositive power, with zero sole voting and dispositive power. The 2,400,985-share disclosures concern securities held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Israel A. Englander. The statement says this is not, by itself, an admission of beneficial ownership by those three reporting persons.
COLLEGIUM PHARMACEUTICAL, INC. (COLL) is the issuer named in a Form 144 notice in which former officer Scott Dreyer reports a proposed sale of 27,419 common shares. The notice lists an aggregate market value of $603,320.70 and an approximate sale date of September 30, 2026, through Fidelity Brokerage Services LLC.
Collegium Pharmaceutical, Inc. (COLL) is reported to have a new significant shareholder group. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,769,122 shares of common stock, representing 5.4% of the class, with shared voting and dispositive power over those shares. Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 1,820,330 shares, or 5.6% of the common stock, all with shared voting and shared dispositive power. The filing notes that securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and related entities, and expressly states that this structure should not, by itself, be construed as an admission of beneficial ownership by Millennium Management LLC, Millennium Group Management LLC, or Mr. Englander.
Fuller & Thaler Asset Management, Inc., a California corporation, reports beneficial ownership of 1,632,780.71 shares of PHARMACEUTICAL, INC common stock (CUSIP 19459J104), representing 5.03% of the class as of June 30, 2026.
Fuller & Thaler has sole voting and sole dispositive power over these shares and no shared voting or dispositive power. The position is held in accounts for advisory clients, each of whom has the right to receive dividends and sale proceeds on the shares.
Collegium Pharmaceutical, Inc. entered into an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This transaction is part of a previously authorized $150 million share repurchase program approved in July 2025.
Collegium will pay $50 million to Jefferies and receive an initial delivery of 1,556,420 shares, calculated using the $25.70 closing stock price on August 12, 2026. This initial delivery represents approximately 80% of the total shares expected to be repurchased under the ASR. The final number of shares will be determined based on the volume-weighted average price of Collegium’s common stock during the ASR period, with final settlement expected no later than the fourth quarter of 2026. As of June 30, 2026, Collegium had approximately 32.5 million shares outstanding.